WO2026069134 - HUMAN THERAPY WITH IL-18 IMMUNOCYTOKINES
National phase entry is expected:
Publication Number
WO/2026/069134
Publication Date
02.04.2026
International Application No.
PCT/IB2025/059574
International Filing Date
23.09.2025
Title **
[English]
HUMAN THERAPY WITH IL-18 IMMUNOCYTOKINES
[French]
THÉRAPIE HUMAINE AVEC DES IMMUNOCYTOKINES À IL-18
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
KREFT, Bertolt
PATTABIRAMAN, Vijaya Raghavan
GOEPFERT, Arnaud
WIGGINTON, Jon
Priority Data
63/699,651
26.09.2024
US
63/706,873
14.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4876 | |
| EPO | Filing, Examination, Granting | 41211 | |
| Japan | Filing, Examination, Granting | 3475 | |
| South Korea | Filing, Examination, Granting | 4676 | |
| USA | Filing, Examination, Granting | 13490 |
Total:
67,728
Contact Us
Abstract[English]
The present disclosure relates to methods of treating cancer in humans with immunocytokine compositions comprising antibodies or antigen binding fragments specific for PD-1 and IL-18 polypeptides. Also described herein are pharmaceutical compositions of such immunocytokine compositions.[French]
La présente divulgation concerne des méthodes de traitement du cancer chez des êtres humains avec des compositions d'immunocytokines comprenant des anticorps ou des fragments de liaison à l'antigène spécifiques de polypeptides PD-1 et IL-18. La divulgation concerne également des compositions pharmaceutiques de telles compositions d'immunocytokines.